Sequential HIV Vaccine Triggers Broad Antibodies in 44% of Primates
Updated
Updated · Forbes · Jul 18
Sequential HIV Vaccine Triggers Broad Antibodies in 44% of Primates
3 articles · Updated · Forbes · Jul 18
Summary
More than half of rhesus macaques given a stepwise HIV vaccine regimen developed the targeted broadly neutralizing antibody class, and 44% produced antibodies in blood that neutralized diverse strains.
The strategy uses a series of immunizations rather than one shot—first activating rare precursor B cells, then steering them through boosters to recognize a key HIV surface region and mature toward broader protection.
One animal reached antibody levels predicted to deliver 75% to 90% protection against diverse HIV strains, while several others hit levels associated with roughly 50% protection.
The regimen also generated long-lived memory B cells that kept maturing with each booster, suggesting the immune system can be deliberately guided toward antibodies that usually arise only after years of infection.
The work remains preclinical and the schedule still needs optimization, but researchers say the germline-targeting approach could inform vaccines against HIV and other fast-evolving viruses.
Scientists can now guide immunity against HIV, but is their complex eight-shot vaccine too impractical for widespread human use?
Amid a historic vaccine breakthrough, can HIV research survive the sudden halt of its primary US government funding?
Breakthrough in HIV Vaccine: Germline-Targeting Strategy Induces Broadly Neutralizing Antibodies in Primates, Human Trials Underway
Overview
A major breakthrough in HIV vaccine research has emerged from recent primate studies, offering new hope in the fight against HIV. Scientists have successfully induced broadly neutralizing antibodies (bnAbs) in primates—antibodies that can target key parts of HIV even as the virus rapidly mutates. This is significant because HIV’s high mutation rate has long made vaccine development difficult. Naturally, these powerful antibodies are very rare in people living with HIV, but the new approach shows it is possible to make them common through vaccination. This achievement marks a pivotal step toward an effective HIV vaccine.